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effectiveness of fecal microbiota transplantation for the treatment of recurrent 
Clostridium difficile infection. The aim of this study is to evaluate the cost-effec-
tiveness of fecal microbiota transplantation compared with vancomycin for the 
treatment of Clostridium difficile infection in Australia. Methods: A Markov model 
was developed to compare the cost-effectiveness of fecal microbiota transplantation 
compared with standard antibiotic therapy. A literature review of clinical evidence 
informed the structure of the model and the choice of parameter values. Clinical 
effectiveness was measured in terms of quality adjusted life years. Uncertainty in 
the model was explored using probabilistic sensitivity analysis. Results: Using 
fecal microbiota transplantation rather than vancomycin saves AU$7,425 (95% CI: 
AU$2,252, AU$12,598) per Clostridium difficile infection patient. Fecal microbiota 
transplantation also leads to an incremental increase of 1.02 (95% CI 0.23, 1.81) 
life-years or 0.87 (95% CI 0.06, 1.68) quality adjusted life years per patient com-
pared with vancomycin. ConClusions: Based on current evidence, fecal micro-
biota transplantation is cost saving compared with standard antibiotic therapy for 
the treatment of recurrent Clostridium difficile infection. More research into the 
long-term safety and quality of life outcomes for patients receiving fecal microbiota 
transplantation is warranted.
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objeCtives: Hepatic encephalopathy (HE) is associated with high morbidity and 
mortality. Rifaximin-α is effective in reducing the recurrence of episodes of overt 
HE, and reduces hospital utilisation. The objective was to characterise the cost effec-
tiveness of rifaximin-α plus a standard of care (SOC) versus SOC alone (lactulose) 
in patients with liver cirrhosis in Belgium. Methods: This economic evaluation 
used a Markov state transition model. The outcome metric was the incremental 
cost effectiveness ratio (ICER), derived from estimates of the cost/quality adjusted 
life years (QALYs). The payer perspective was that of the Belgian healthcare system. 
Outcome data were from two trials of rifaximin-α . Belgian costs data (2010) were 
derived from published sources. Health-related utility was estimated indirectly from 
disease-specific quality of life RCT data. The time horizon was five years. Costs and 
benefits were discounted at 3% and 1.5%, respectively. Real world data were also 
applied into the model for length of hospital stay (LOHS) and number of admis-
sions. Results: Average costs of the included elements of care were € 31,262 in 
the rifaximin-α + SOC arm and € 44,190 in the SOC arm, a difference of € 12,927. The 
corresponding values for benefit were 2.5 and 1.9 QALYs per person, respectively, 
a difference of 0.6 QALYs over the five year period. This translated into a dominant 
base-case ICER at five years, ten years and for a lifetime simulation, meaning that 
compared to SOC, rifaximin-α + SOC improves quality of life and offers savings to 
the Belgian healthcare system. Key parameters impacting the ICER included LOHS 
and number of hospital admissions. ConClusions: By reducing overt HE episodes, 
the likelihood of hospital admission and LOHS, rifaximin-α 550 mg + SOC in patients 
with recurrent HE in the context of liver cirrhosis, represented good value and was 
cost-saving compared with SOC.
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objeCtives: The aim of this study was assessing cost-utility of infliximab compared 
with current treatments in patients with moderate to severe ulcerative colitis (UC) in 
Iran. Methods: We constructed a decision tree model with 5 year time horizon to 
follow up 1000 hypothetical patients for estimating treatment costs and outcomes. 
Patients were individuals with moderate to severe UC that is resistant to current 
treatments. Remission rate, clinical response and surgery were selected as clini-
cal outcomes. Then for estimating QALY, utility value related to each state drive 
form published literature. We also estimated associated probabilities using patients 
‘medical records and specialists’ opinion. Costs of treatment including physician 
visits, laboratory tests, hospitalizations, surgery and drugs were estimated based on 
the public and private sector tariffs and drug price list that set by pricing committee 
of food and drug administration. Infliximab costs at dosage of 5 mg /kg were cal-
culated for UC patients with average weight of 75 kilogram. Results: Incremental 
cost-utility ratio of infliximab treatment in UC patients estimated with public and 
private sector tariffs were 18 260 and 188 366 dollars per QALY gained compared with 
current treatments, respectively. ConClusions: According to recommendation of 
world health organization for choosing cost effective intervention, interventions 
with relative cost effectiveness value less than 3 time of gross domestic production 
per capita are cost –effective. So for UC patients, our finding indicates that ICUR 
values with public and private sector tariffs are more than 3 time of local GDP 
per capita, 3.8 and 39.5 respectively and infliximab treatment is not cost effective.
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objeCtives: Calcineurin inhibitors represent the cornerstone of immunosuppres-
sive therapy after liver transplantation. A recent Bayesian network meta-analysis 
model. These included the rates of response and remission during the induction 
period. Adverse events were also important; however, only those for standard care 
were key drivers in the submission, while adverse event rates for both treatments 
were important in the reconstructed model. ConClusions: Rates of response, 
remission and adverse events are important drivers of cost effectiveness in Crohn’s 
disease.
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objeCtives: Compared to infection with hepatitis C virus (HCV) alone, patients 
co-infected with HIV have faster disease progression, decreased quality of life 
and increased rates of mortality. The objective of this study was to compare 
the cost-effectiveness of novel, all oral direct-acting antiviral regimens for the 
treatment of HCV/HIV co-infected patients. Methods: A published, validated 
Markov model was used to model a cohort of HCV/HIV co-infected patients 
(mean age 50 years, 50% female, evenly distributed across F0–F4) treated with 12 
weeks daclatasvir+sofosbuvir (DCV+SOF) versus 24 weeks sofosbuvir+ribavirin 
(SOF+RBV). Clinical inputs were obtained from a matching-adjusted indirect 
comparison (MAIC) of ALLY-2 (DCV+SOF: adjusted SVR= 100.0%) and PHOTON-1/-2 
(SOF+RBV: adjusted SVR= 84.6%). HIV co-infection- and HCV genotype-specific 
transition rates were applied and analyses combined and weighted per MAIC 
values (genotypes 1 & 4= 56.5%; 2= 16.5%; and 3= 27.0%). UK acquisition costs 
(DCV= £2,043.15, SOF= £2,915.24 and RBV= £66.95 per week), disease state costs 
(2014) and health utility values were used. Costs and benefits were discounted 
at 3.5%. Results: Reduced total costs and increased QALYs were estimated for 
DCV+SOF versus SOF+RBV, resulting in DCV+SOF dominating in terms of cost-
effectiveness. Predicted discounted total costs were £239,213 versus £250,014, 
respectively. Whilst the cost of HIV management increased by £5,237 per person 
due to the increase in life expectancy (19.20 discounted years versus 18.64) with 
DCV+SOF, there was a reduction in HCV management costs of £5,695 as a conse-
quence of avoiding end-stage liver disease (ESLD) complications. Predicted dis-
counted QALYs were 11.56 versus 10.91, respectively. ConClusions: The results 
of this analysis demonstrate that significant value might be realised by the use of 
DCV+SOF over SOF+RBV in patients co-infected with HIV and HCV. Cost-savings 
and QALY gains for the DCV+SOF regimen are driven by the shorter treatment 
duration and higher SVR, resulting in lower overall acquisition costs and fewer 
ESLD complications.
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objeCtives: Gut-directed hypnotherapy (HT) is effective for irritable bowel syn-
drome (IBS) and functional abdominal pain (syndrome) (FAP(S)) in children. We 
assessed the cost-utility and cost-effectiveness of HT by self-exercises at home 
using a compact disc (CD) against individual HT performed by a qualified hypno-
therapist (iHT). Methods: Alongside a multicentre non-inferiority randomized 
controlled trial among children with IBS and FAP(S) data on treatment response, 
quality of life (Health Utility Index 3) and societal and health care costs were 
gathered at baseline (T0), end of treatment (T1) and 6 (T2) and 12 (T3) months 
thereafter. Incremental cost-effectiveness ratios with the extra costs per responder 
and per QALY were estimated and the cost-effectiveness acceptability of CD was 
assessed for various levels of willingness to pay (WTP) following non-parametric 
bootstrapping. Results: After one year, CD treatment resulted in cost savings 
of € 397 (95% bca CI: -€ 794 to -€ 26; P= 0.038) compared to iHT. Treatment response 
in the CD group (62.1%) was non-inferior to the iHT group (71.1%). Offering CD 
treatment instead of iHT treatment saves € 4,411 per treatment non-responder. 
After correction for differences in health utility at baseline, the mean difference 
in QALYs (0.014 (95% bca CI: -0.032 to 0.060) slightly favoured CD treatment. The 
probability that CD treatment is both, cost saving and gaining QALYs, equals 69.7%; 
the probability that CD is cost-effective equals 0.825 at a reasonable WTP in chil-
dren of € 50,000. ConClusions: Home-based treatment with HT exercises on CD 
for children with IBS or FAP(S) is non-inferior and seems cost-effective compared 
to individual HT with a qualified therapist and could therefore be offered as first 
line treatment.
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objeCtives: Clostridium difficile is the most common cause of hospital-acquired 
diarrhea in Australia. In 2013, a randomized controlled trial demonstrated the 
